Table 2.

Common drugs used in recent clinical studies for platinum-resistant ovarian cancer.

	Number (%)	Subjects	RR (%)
Clinical trials (n=40)
Gemcitabine	10 (25%)	430	22.3
Pegylated liposomal doxorubicin	8 (20%)	339	22.4
Topotecan	4 (10%)	96	19.9
Cisplatin	3 (7.5%)	114	21.9
Docetaxel	3 (7.5%)	61	19.7
Non-trial studies (n=20)
Gemcitabine	6 (30%)	141	22.7
Paclitaxel	4 (20%)	89	39.3
Topotecan	3 (15%)	113	17.8
Carboplatin	3 (15%)	62	27.4
Pegylated liposomal doxorubicin	2 (10%)	53	28.3
Bevacizumab	2 (10%)	32	37.5

Analysis of 60 clinical studies published between January 2005 and March 2010.

Abbreviations: Number, number of clinical studies; Subjects, sum of enrolled patients in clinical studies; and RR, average response rate in any regimens using the listed agent.